Adlai Nortye Doses First Patient In Randomized Phase II Clinical Trial of Palupiprant For Treatment Of Locally Advanced Rectal Cancer With Radiation Therapy
Portfolio Pulse from Benzinga Newsdesk
Adlai Nortye has dosed the first patient in a randomized Phase II clinical trial of Palupiprant for the treatment of locally advanced rectal cancer in combination with radiation therapy.
May 22, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adlai Nortye has initiated a Phase II clinical trial for Palupiprant, targeting locally advanced rectal cancer in combination with radiation therapy. This marks a significant step in the development of their oncology pipeline.
The initiation of a Phase II clinical trial is a critical milestone in drug development, indicating progress and potential future revenue if the trial is successful. This news is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100